ethyl 2-hydroxy-8-nonenoate | 1351391-24-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: ethyl 2-hydroxy-8-nonenoate
• 英文别名: Ethyl 2-hydroxynon-8-enoate；ethyl 2-hydroxynon-8-enoate
• CAS: 1351391-24-6
• 化学式: C₁₁H₂₀O₃
• 分子量: 200.278
• InChiKey: SNDVYBDOFARBEX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  14
• 可旋转键数：
  9
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.73
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  ethyl 2-hydroxy-8-nonenoate 在 Zhan-1b 、 水 、 1,2-二氯乙烷 、 N,N-二异丙基乙胺 、 lithium hydroxide 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基甲酰胺 、 叔丁醇 为溶剂， 反应 1.5h， 生成
  参考文献：
  名称：

  Discovery of novel P3-oxo inhibitor of hepatitis C virus NS3/4A serine protease

  摘要：

  A novel series of P3 oxo-modified macrocyclic hepatitis C virus NS3/4A serine protease inhibitor was designed, synthesized and biologically evaluated. The hydroxy-substituted inhibitor 10 demonstrated high potency in genotype 1a and 1b replicon and in the panel of HCV protease mutants. Interestingly, the t-butyl carbonate analog 9c, while not the most potent one in this series, exhibited a virtually flat potency profile in the panel of HCV protease mutants, thus providing opportunity for further optimization. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.02.039
• 作为产物：
  描述：

  乙醛酸乙酯 、 7-溴-1-庚烯 在 碘 、 magnesium 作用下， 以 四氢呋喃 为溶剂， 反应 4.0h， 生成 ethyl 2-hydroxy-8-nonenoate
  参考文献：
  名称：

  Discovery of novel P3-oxo inhibitor of hepatitis C virus NS3/4A serine protease

  摘要：

  A novel series of P3 oxo-modified macrocyclic hepatitis C virus NS3/4A serine protease inhibitor was designed, synthesized and biologically evaluated. The hydroxy-substituted inhibitor 10 demonstrated high potency in genotype 1a and 1b replicon and in the panel of HCV protease mutants. Interestingly, the t-butyl carbonate analog 9c, while not the most potent one in this series, exhibited a virtually flat potency profile in the panel of HCV protease mutants, thus providing opportunity for further optimization. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.02.039

文献信息

• [EN] HCV INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF<br/>[FR] COMPOSÉS INHIBITEURS DU VIRUS DE L'HÉPATITE C (HCV) ET LEURS PROCÉDÉS D'UTILISATION
  申请人：ANACOR PHARMACEUTICALS INC

  公开号：WO2011150190A2

  公开（公告）日：2011-12-01

  The present invention features compounds of Formula (I), (II) and (III), pharmaceutical compositions and use in the treatment of viral disease:
• Discovery of novel P3-oxo inhibitor of hepatitis C virus NS3/4A serine protease
  作者：Maosheng Duan、Wieslaw Kazmierski、Renae Crosby、Margaret Gartland、Jinjing Ji、Matt Tallant、Amy Wang、Robert Hamatake、Lois Wright、Min Wu、Yong-Kang Zhang、Charles Z. Ding、Xianfeng Li、Yang Liu、Suoming Zhang、Yasheen Zhou、Jacob J. Plattner、Stephen J. Baker

  DOI：10.1016/j.bmcl.2012.02.039

  日期：2012.4

  A novel series of P3 oxo-modified macrocyclic hepatitis C virus NS3/4A serine protease inhibitor was designed, synthesized and biologically evaluated. The hydroxy-substituted inhibitor 10 demonstrated high potency in genotype 1a and 1b replicon and in the panel of HCV protease mutants. Interestingly, the t-butyl carbonate analog 9c, while not the most potent one in this series, exhibited a virtually flat potency profile in the panel of HCV protease mutants, thus providing opportunity for further optimization. (C) 2012 Elsevier Ltd. All rights reserved.